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Background: Disorders of oxidative phosphorylation affects 1/5000 individuals and present heterogeneous
involvement of tissues highly dependent upon ATP production.
Case presentation: Here we present the case of a 48-year-old woman carrying a homozygous mutation (p.A899T)
in mitochondrial polymerase gamma (POLG) and manifesting with a complex neurological phenotype including
Dopamine-agonist responsive Parkinsonism.
Conclusion: This case report is further evidence that mitochondrial dysfunction might play a role in Parkinson’s
Disease pathogenesis and helps in identification of apparent mutation-specific clinical characteristics. Mutations in
POLG should be looked for in cases of Parkinsonism, especially when multisystem neurological involvement is
found.
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The mitochondrial polymerase gamma (POLG) repre-
sents a major human disease gene and may account for
up to 25% of all mitochondrial diseases, at least in UK
and in Italy [1]. Among the possible clinical presenta-
tions, Alpers-Huttenlocher syndrome (AHS) in children
and inherited progressive external ophthalmoparesis
(PEO) in adults — either as the sole manifestation or in
association with additional neurological features [2,3] —
are the most common. Movement disorders are possible
manifestations in AHS and have occasionally been de-
scribed in adult PEO [4].
Case presentation
Here we report on a patient carrying a homozygous
mutation in POLG and manifesting with a complex
neurological phenotype fitting the clinical diagnosis of
SANDO (sensory ataxic neuropathy, dysarthria, and* Correspondence: monicabandettini@yahoo.it
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responsive Parkinsonism.
A 48-year-old Italian woman, born to non-consan-
guineous parents, and with a negative family history, was
healthy until age 26 when she developed bilateral PEO
and ptosis. At that age, electromyography showed myo-
pathic features and a limb skeletal muscle biopsy was said
to be compatible with mitochondrial myopathy, but whole
mtDNA analysis was negative. At age 36, the proposita de-
veloped proximal and distal weakness in lower limbs, and
sensory ataxia. A diagnosis of demyelinating sensory-
motor neuropathy was considered on the basis of nerve
conduction studies and sural nerve biopsy (Figure 1a).
Anxiety-mood disorders became evident and treatment
with SSRI was started (Fluoxetine 40 mg/day) with benefit.
Histochemical and biochemical examination of a second
muscle biopsy, using established methodologies for inves-
tigation of oxidative metabolism [5] showed “ragged blue”,
cytochrome c oxidase negative muscle fibers (Figure 1b)
and a partial biochemical reduction of activities of com-
plex I and IV. At 47 years, the patient was referred to our
attention because of onset of resting and attitudinal handoMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Findings of nerve biopsy (semithin section in blue toluidine) and muscle sections stained for cytochrome c oxidase (COX)
and succinate dehydrogenase (SDH) reactions. a: Nerve biopsy shows loss of both small and large nerve fibers. b: Muscle biopsy shows
several fibers with absence of COX activity (arrow) and marked mitochondrial proliferation, as shown by their strong SDH reaction.
Figure 2 I-FP-CIT SPECT imaging of the dopamine transporter.
The imaging of the dopamine transporter revealed reduced binding
in both striata, more severe in the right putamen.
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examination showed PEO, bilateral ptosis, signs of sen-
sorimotor neuropathy with ataxic gait and positive Rom-
berg sign, head and limbs tremor plus rigidity. Unified
Parkinson’s Disease Rating Scale-UPDRS motor score was
39. Cognition was mildly affected upon MMSE examin-
ation, and anxiety and obsessive disorder were evident.
Creatine kinase levels were 217 U/L (normal < 168) and
myoglobin was 360 U/L (normal <75). A brain MRI
showed mild cortical atrophy. I-FP-CIT SPECT imaging
of the dopamine transporter revealed reduced binding in
both striata (Figure 2). Dopamine agonist treatment
(Pramipexole R.P. 0.52 mg/day) was started with improve-
ment in tremor and ambulation (UPDRS III = 29). After a
10-month follow up, the patient remains on treatment
with Pramipexole R.P. (1.05 mg/day) and Duloxetine
(60 mg/day) with a stable neurological condition.
The 82-year-old mother and two of the four living sis-
ters, aged 57 and 45 years, had a normal neurological
examination. The father of the proposita had died at the
age of 72 because of myocardial infarction but he was
referred to be free of neurological complaints.
Having obtained written informed consent, genomic
DNA was extracted from peripheral blood of the patient
and her living relatives using the MagNa Pure System
(Roche) and the whole coding region and flanking
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using the BigDye 3.1 chemistry (Applied Biosystems,
Foster City, CA). In the proposita we identified a homozy-
gous c.2665G >A/p.A889T change (Figure 3a). The muta-
tion was heterozygous in her mother and two sisters and
led to a reduction of the protein in skeletal muscle hom-
ogenate (Figure 3b). No mutations in other genes associ-
ated with multiple mtDNA deletions were detected [6].
There was no mtDNA depletion in muscle.
Conclusion
The present report offers two main considerations. The
patient we described combines the clinical features
of SANDO syndrome complicated with late-onset
Parkinsonism and mood disorder. In previous years, co-
existence of Parkinsonism and POLG mutations has
been described, suggesting that mitochondrial dysfunc-
tion might play a role in the pathogenesis of PD [7]. Our
case report is further evidence that abnormal oxidative
metabolism and loss of mtDNA integrity might be impli-
cated in similar conditions. Whilst is evident that POLG
does not represent a frequent etiology in PD-likeFigure 3 Electropherogram of POLG (a) and Western blot and densito
Germany) in the patient and a control. a: The electropherogram with th
(c.2665G>A) identified in the patient. The electropherogram of a control is
muscle homogenate were loaded in each lane. POLG content was normali
Levels of expression in the patient appear reduced (about 45% of control ssyndromes, it seems not too speculative to hypothesize
that alterations in mtDNA fidelity and subsequent
impaired protein synthesis likely compromise mitochon-
drial bioenergetics, dynamics, transport, or their com-
bination, in dopaminergic neurons [8]. Similar to other
cases of “mitochondrial parkinsonisms”, our patient had
benefit with antiparkinson drugs, underling the import-
ance of a correct diagnosis [4,9-12].
A further consideration emerges from the evidence
of an additional association between the POLG p.A899T
variant and SANDO syndrome. The p.A899T has
initially been described in compound heterozygosity
[13,14] and frequently associated with the clinical triad
of sensory ataxic, ptosis, and PEO together with a mood
disorder and a movement disorder such as Dopamine-
agonist responsive parkinsonism. In the face of an ever
increasing, pleiomorphic array of features associated
with mutations in POLG [15], identification of apparent
mutation-specific clinical characteristics might facilitate
molecular confirmation in complex patients, prevent
possible co-morbidities, and permit to adopt effective
symptomatic therapies.metric analysis of POLG protein (b) (1:100, ACRIS antibodies,
e region of the exon 17 of POLG flanking the homozygous mutation
also shown. Arrow indicates the mutation. b: About 50 μg of skeletal
zed using a monoclonal SDHA antibody (1:500, Mitosciences, USA).
ample). A representative experiment is shown.
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